Hutchmed (China) (HKG:0013) said it began a phase 3 clinical trial of HMPL-760 in combination with R-GemOx in China, according to a Hong Kong bourse filing Monday.
The firm is studying the combo as a treatment for a type of blood cancer known as diffuse large B-cell lymphoma.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.